JP2021514948A5 - - Google Patents
Info
- Publication number
- JP2021514948A5 JP2021514948A5 JP2020544019A JP2020544019A JP2021514948A5 JP 2021514948 A5 JP2021514948 A5 JP 2021514948A5 JP 2020544019 A JP2020544019 A JP 2020544019A JP 2020544019 A JP2020544019 A JP 2020544019A JP 2021514948 A5 JP2021514948 A5 JP 2021514948A5
- Authority
- JP
- Japan
- Prior art keywords
- average molecular
- molecular weight
- powder
- nanoparticles
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635088P | 2018-02-26 | 2018-02-26 | |
| US62/635,088 | 2018-02-26 | ||
| PCT/IL2019/050217 WO2019162951A1 (en) | 2018-02-26 | 2019-02-26 | Drug delivery systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514948A JP2021514948A (ja) | 2021-06-17 |
| JP2021514948A5 true JP2021514948A5 (enExample) | 2022-03-09 |
| JP7416430B2 JP7416430B2 (ja) | 2024-01-17 |
Family
ID=65763696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544019A Active JP7416430B2 (ja) | 2018-02-26 | 2019-02-26 | 薬物送達システム |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210128534A1 (enExample) |
| EP (1) | EP3758677A1 (enExample) |
| JP (1) | JP7416430B2 (enExample) |
| KR (2) | KR102717886B1 (enExample) |
| CN (1) | CN112004524B (enExample) |
| AU (1) | AU2019226051B2 (enExample) |
| CA (1) | CA3092016A1 (enExample) |
| IL (1) | IL276784B2 (enExample) |
| WO (1) | WO2019162951A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| GB201810923D0 (en) * | 2018-07-03 | 2018-08-15 | Blueberry Therapeutics Ltd | Compositions and method of treatment |
| GB201810925D0 (en) * | 2018-07-03 | 2018-08-15 | Blueberry Therapeutics Ltd | Compositions and methods of treatment |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| MX2022006824A (es) * | 2019-12-05 | 2022-09-19 | Univ West Virginia | Nanoesferas de plga cargadas con proteinas. |
| CA3174988A1 (en) * | 2020-03-11 | 2021-09-16 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| AU2021291438A1 (en) * | 2020-06-19 | 2023-02-16 | Cannovex Bv | Pulmonary formulation comprising cannabinoids |
| AU2021317263B2 (en) | 2020-07-29 | 2024-08-01 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
| EP4057993A2 (en) | 2020-07-29 | 2022-09-21 | Karnak Technologies, LLC | Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils |
| IL300676A (en) * | 2020-08-20 | 2023-04-01 | Bionanosim Bns Ltd | A lipid system for the administration of OCA |
| DK202070707A1 (en) | 2020-10-26 | 2022-05-02 | Jacob Holm & Sons Ag | Dry CBD Delivery Fabric |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
| US12667578B2 (en) | 2024-07-25 | 2026-06-30 | Visionary Assets, Llc | Cryogenic process for making cannabinoid nanoparticles and compositions made thereby |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4851067B2 (ja) * | 2004-01-28 | 2012-01-11 | ホソカワミクロン株式会社 | ナノ粒子含有組成物およびその製造方法 |
| EP1655021B1 (en) * | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
| CA2578176C (en) * | 2004-11-09 | 2013-09-24 | Novagali Pharma Sa | Ophthalmic emulsions containing an immunosuppressive agent |
| CN1903365A (zh) * | 2005-07-28 | 2007-01-31 | 中国医学科学院生物医学工程研究所 | 载药纳米微粒及其制备方法和该微粒在制备抗血管再狭窄制剂中的应用 |
| ES2425969T3 (es) * | 2007-04-27 | 2013-10-18 | Kyushu University, National University Corporation | Agente para el tratamiento de enfermedades pulmonares |
| CN101810563B (zh) * | 2009-09-25 | 2012-04-25 | 宋洪涛 | 他克莫司眼用在体凝胶制剂及其制备方法 |
| JP6112615B2 (ja) * | 2011-01-24 | 2017-04-12 | イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． | 薬物の皮膚及び全身送達のためのナノ粒子 |
| US20170065533A1 (en) * | 2011-01-24 | 2017-03-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Nanoparticles for dermal and systemic delivery of drugs |
| HK1205461A1 (zh) * | 2012-02-22 | 2015-12-18 | Trustees Of Tufts College | 用於眼部传输治疗剂的组合物和方法 |
| US9724304B2 (en) * | 2012-06-14 | 2017-08-08 | Temple University—Of the Commonwealth System of Higher Education | Nanospheres for therapeutic agent delivery |
| CN102772827B (zh) * | 2012-07-13 | 2014-05-07 | 华南理工大学 | Plga/羟基磷灰石/碳酸钙复合微球及其制备方法 |
| BR112016012063B1 (pt) * | 2013-12-31 | 2021-02-23 | Pb&B Sa | composição e usos da mesma |
| EP3154524B1 (en) * | 2014-06-12 | 2021-12-15 | Adare Pharmaceuticals USA, Inc. | Extended-release drug delivery compositions |
| GB201419540D0 (en) * | 2014-11-03 | 2014-12-17 | Nanomerics Ltd | Delivery of drugs |
| CN105769821B (zh) * | 2016-04-19 | 2019-06-14 | 浙江工业大学 | 他克莫司自组装聚合物纳米粒给药系统及其制备方法 |
-
2019
- 2019-02-26 KR KR1020207027934A patent/KR102717886B1/ko active Active
- 2019-02-26 JP JP2020544019A patent/JP7416430B2/ja active Active
- 2019-02-26 IL IL276784A patent/IL276784B2/en unknown
- 2019-02-26 KR KR1020247033602A patent/KR102810631B1/ko active Active
- 2019-02-26 WO PCT/IL2019/050217 patent/WO2019162951A1/en not_active Ceased
- 2019-02-26 CN CN201980027345.7A patent/CN112004524B/zh active Active
- 2019-02-26 US US16/971,465 patent/US20210128534A1/en active Pending
- 2019-02-26 CA CA3092016A patent/CA3092016A1/en active Pending
- 2019-02-26 EP EP19710805.3A patent/EP3758677A1/en active Pending
- 2019-02-26 AU AU2019226051A patent/AU2019226051B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanna et al. | Polymeric nanoparticles encapsulating white tea extract for nutraceutical application | |
| Ong et al. | Chitosan-propolis nanoparticle formulation demonstrates anti-bacterial activity against Enterococcus faecalis biofilms | |
| Adlravan et al. | Potential activity of free and PLGA/PEG nanoencapsulated nasturtium officinale extract in inducing cytotoxicity and apoptosis in human lung carcinoma A549 cells | |
| Li et al. | Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: An in vitro study | |
| Cosco et al. | Rutin-loaded chitosan microspheres: Characterization and evaluation of the anti-inflammatory activity | |
| Nathiya et al. | Quercetin, encapsulated quercetin and its application—A review | |
| Wang et al. | Nanoceria‐loaded injectable hydrogels for potential age‐related macular degeneration treatment | |
| Popat et al. | Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity | |
| Mobahat et al. | Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model | |
| Matokanovic et al. | Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90 | |
| Kustiawan et al. | New insights of propolis nanoformulation and its therapeutic potential in human diseases | |
| Karavelioglu et al. | Preparation of chitosan nanoparticles as Ginkgo Biloba extract carrier: In vitro neuroprotective effect on oxidative stress-induced human neuroblastoma cells (SH-SY5Y) | |
| Khatoon et al. | Nanoencapsulation of polyphenols as drugs and supplements for enhancing therapeutic profile-a review | |
| Wahab et al. | Nanomaterials for the delivery of Herbal Bioactive Compounds | |
| Özakar et al. | A comprehensive study on peppermint oil and cinnamon oil as nanoemulsion: preparation, stability, cytotoxicity, antimicrobial, antifungal, and antioxidant activity | |
| Nguyen et al. | Chitosan/cyclodextrin surface-adsorbed naringenin-loaded nanocapsules enhance bacterial quorum quenching and anti-biofilm activities | |
| Alamoudi et al. | Chitosan/hesperidin nanoparticles formulation: a promising approach against ethanol-induced gastric ulcers via Sirt1/FOXO1/PGC-1α/HO-1 pathway | |
| Hoyos-Ceballos et al. | Design of epigallocatechin gallate loaded PLGA/PF127 nanoparticles and their effect upon an oxidative stress model | |
| El-Sherbiny et al. | Fabrication and assessment of potent anticancer nanoconjugates from chitosan nanoparticles, curcumin, and eugenol | |
| Villate et al. | Development, characterization and in vitro gastrointestinal release of PLGA nanoparticles loaded with full-spectrum cannabis extracts | |
| Bona et al. | Antitumoral activity of Cecropia pachystachya leaves extract in vitro and in vivo model of rat glioma: Brain and blood effects | |
| Mishra et al. | A review of various pharmacological effects of quercetin with its barriers and approaches for solubility and permeability enhancement | |
| Quiroz-Reyes et al. | Development and characterization of gelatin nanoparticlesloaded with a cocoa-derived polyphenolic extract | |
| Fadl Allah et al. | Profiling the volatile composition and cytotoxic assessment of the encapsulated Spirulina Platensis using alginate chitosan nanoparticles | |
| García-López et al. | Zebrafish, a model to develop nanotherapeutics that control neutrophils response during inflammation |